Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)

NCT07136012 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT07136012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07136012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Recruiting
Start date
August 22, 2025
Completion date
October 20, 2031
Enrollment
11,000 (estimated)
Sites
252

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease